Evidence synthesis from aggregate recurrent event data for clinical trial design and analysis
暂无分享,去创建一个
[1] Jean-Michel Marin,et al. Approximate Bayesian computational methods , 2011, Statistics and Computing.
[2] W. Busse,et al. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. , 2014, The Lancet. Respiratory medicine.
[3] G R Wood. Confidence and prediction intervals for generalised linear accident models. , 2005, Accident; analysis and prevention.
[4] J. Lawless. Negative binomial and mixed Poisson regression , 1987 .
[5] J. Bird,et al. Mepolizumab for Severe Eosinophilic Asthma (DREAM): A Multicentre, Double-Blind, Placebo-Controlled Trial , 2013, Pediatrics.
[6] K Ulm,et al. A simple method to calculate the confidence interval of a standardized mortality ratio (SMR) , 1990, American journal of epidemiology.
[7] Andrew Gelman,et al. General methods for monitoring convergence of iterative simulations , 1998 .
[8] Brandon M. Turner,et al. Hierarchical Approximate Bayesian Computation , 2013, Psychometrika.
[9] J. L. Folks,et al. Complete sufficiency and maximum likelihood estimation for the two-parameter negative binomial distribution , 1986 .
[10] S. Willsie. Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia , 2010 .
[11] I. Pavord,et al. Mepolizumab treatment in patients with severe eosinophilic asthma. , 2015, The New England journal of medicine.
[12] Ana Sousa,et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. , 2009, The New England journal of medicine.
[13] Jiqiang Guo,et al. Stan: A Probabilistic Programming Language. , 2017, Journal of statistical software.
[14] Tim Friede,et al. Meta‐analysis of two studies in the presence of heterogeneity with applications in rare diseases , 2016, Biometrical journal. Biometrische Zeitschrift.
[15] A Whitehead,et al. Borrowing strength from external trials in a meta-analysis. , 1996, Statistics in medicine.
[16] Bradley P Carlin,et al. Detecting outlying trials in network meta‐analysis , 2015, Statistics in medicine.
[17] Tim Friede,et al. Evidence synthesis for count distributions based on heterogeneous and incomplete aggregated data , 2013, Biometrical journal. Biometrische Zeitschrift.
[18] M. Sydes,et al. Practical methods for incorporating summary time-to-event data into meta-analysis , 2007, Trials.
[19] D. Spiegelhalter,et al. Summarizing historical information on controls in clinical trials , 2010, Clinical trials.
[20] Gagandeep Kang,et al. Analysis of human immune responses in quasi-experimental settings: tutorial in biostatistics , 2012, BMC Medical Research Methodology.
[21] David J Spiegelhalter,et al. A re-evaluation of random-effects meta-analysis , 2009, Journal of the Royal Statistical Society. Series A,.
[22] Heinz Schmidli,et al. Using historical control information for the design and analysis of clinical trials with overdispersed count data , 2013, Statistics in medicine.
[23] Tim Friede,et al. Meta‐analysis of few small studies in orphan diseases , 2016, Research synthesis methods.
[24] E. W. Barnes. The Asymptotic Expansion of Integral Functions Defined by Generalised Hypergeometric Series , 1907 .
[25] J A Anderson,et al. Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited , 2008, European Respiratory Journal.
[26] Daniel Jackson,et al. A refined method for multivariate meta-analysis and meta-regression , 2013, Statistics in medicine.
[27] F. Garwood,et al. i) Fiducial Limits for the Poisson Distribution , 1936 .
[28] Nicky J Welton,et al. Evidence Synthesis for Decision Making in Healthcare , 2012 .
[29] S J Pocock,et al. The combination of randomized and historical controls in clinical trials. , 1976, Journal of chronic diseases.
[30] Nicky J Welton,et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves , 2012, BMC Medical Research Methodology.
[31] I. Pavord,et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. , 2014, The New England journal of medicine.
[32] D. Berry,et al. Bayesian Survival Analysis With Nonproportional Hazards , 2004 .
[33] S. Wenzel,et al. Dupilumab in persistent asthma with elevated eosinophil levels. , 2013, The New England journal of medicine.
[34] Rebecca M Turner,et al. Characteristics of meta-analyses and their component studies in the Cochrane Database of Systematic Reviews: a cross-sectional, descriptive analysis , 2011, BMC medical research methodology.
[35] Nicky J Welton,et al. Evidence Synthesis for Decision Making in Healthcare: Welton/Evidence Synthesis for Decision Making in Healthcare , 2012 .
[36] Paul Marjoram,et al. Markov chain Monte Carlo without likelihoods , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[37] A. Gelman. Prior distributions for variance parameters in hierarchical models (comment on article by Browne and Draper) , 2004 .
[38] Frank Bretz,et al. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint , 2007, Statistics in medicine.
[39] M. Parmar,et al. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. , 1998, Statistics in medicine.
[40] R. Maciuca,et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies , 2015, Thorax.
[41] M. A. Best. Bayesian Approaches to Clinical Trials and Health‐Care Evaluation , 2005 .
[42] B. Holzhauer. Meta‐analysis of aggregate data on medical events , 2017, Statistics in medicine.
[43] William J. Browne,et al. Bayesian and likelihood-based methods in multilevel modeling 1 A comparison of Bayesian and likelihood-based methods for fitting multilevel models , 2006 .
[44] Theo Stijnen,et al. Meta‐analysis of summary survival curve data , 2008, Statistics in medicine.
[45] Krishna K. Saha. Interval estimation of the over‐dispersion parameter in the analysis of one‐way layout of count data , 2011, Statistics in medicine.
[46] T Friede,et al. Blinded Sample Size Reestimation with Negative Binomial Counts in Superiority and Non-inferiority Trials , 2010, Methods of Information in Medicine.
[47] Dipak D. Patil,et al. COMPARISON OF CONFIDENCE INTERVALS FOR THE POISSON MEAN: SOME NEW ASPECTS , 2012 .
[48] Anthony O'Hagan,et al. Assurance in clinical trial design , 2005 .
[49] Nicky J Welton,et al. NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials , 2011 .
[50] Paula R Williamson,et al. Aggregate data meta‐analysis with time‐to‐event outcomes , 2002, Statistics in medicine.
[51] E. Bateman,et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. , 2015, The Lancet. Respiratory medicine.
[52] D. Moher,et al. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials , 2010, BMC medicine.
[53] O. Keene,et al. Analysis of exacerbation rates in asthma and chronic obstructive pulmonary disease: example from the TRISTAN study , 2007, Pharmaceutical statistics.
[54] C. Adams,et al. The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS) prisons project pilot study: protocol for a randomised controlled trial comparing dihydrocodeine and buprenorphine for opiate detoxification , 2007, Trials.
[55] A. Cameron,et al. Regression Analysis of Count Data by A. Colin Cameron , 2013 .
[56] Anthony O'Hagan,et al. Robust meta‐analytic‐predictive priors in clinical trials with historical control information , 2014, Biometrics.